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Summary
 
Elevated levels of the p53 protein occur in 
 
,
 
50% of human malignancies,
 
 
 
which makes it an
excellent target for a broad-spectrum T cell immunotherapy of cancer. A major barrier to the
design of p53-specific immunotherapeutics and vaccines, however, is the possibility that T cells
may be tolerant of antigens derived from wild-type p53 due to its low level of expression in
normal
 
 
 
thymus and lymphohemopoetic cells. The combination of p53 deficient (p53
 
2
 
/
 
2
 
) and
p53
 
1
 
/
 
1
 
 HLA-A2.1/K
 
b
 
 transgenic mice was used as a model to explore the possibility that A2.1-
restricted cytotoxic T lymphocytes (CTL) are functionally tolerant of self peptides derived
from the wild-type p53 tumor suppressor protein. A2.1-restricted CTL specific for a naturally
processed p53 self-epitope spanning residues 187-197 were completely aborted in p53
 
1
 
/
 
1
 
 as
opposed to p53
 
2
 
/
 
2
 
 transgenic mice. In contrast, CTL specific for a second self-epitope span-
ning residues 261-269 of the murine p53 sequence were detected in both p53
 
2
 
/
 
2
 
 and p53
 
1
 
/
 
1
 
A2.1/K
 
b
 
 transgenic mice. However, the avidity of the CTL effectors obtained from p53
 
1
 
/
 
1
 
mice was 10-fold lower than that obtained from p53
 
2
 
/
 
2
 
 mice, again suggesting elimination of
CTL with high avidity for the A2.1-peptide complex. The circumvention of functional toler-
ance of high avidity CTL may therefore be a necessary prerequisite for optimizing immuno-
therapy against A2.1-restricted wild-type p53 epitopes in humans.
 
P
 
eptides presented by class I MHC molecules and de-
rived from normal self-proteins that are expressed at ele-
vated levels by cells from a wide variety of human (Hu)
 
1
 
 ma-
lignancies provide, in theory, potential target antigens for a
broad-spectrum, CTL-based immunotherapy of cancer. The
Hu p53 tumor suppressor protein is an excellent source for
such general, tumor-associated and class I MHC–bound
CTL epitopes
 
 
 
as its
 
 
 
expression is markedly upregulated in
many different types of tumor cells. Such overexpression
correlates with the presence of mutation within p53 that in-
activates its normal activity in tumor supression (1, 2).
 
 
 
Due
to the diversity of mutations in p53 that can arise in tu-
mors, if this protein is to serve as a general tumor antigen, it
would be necessary to target peptides representative of the
wild-type (WT) sequence. However, since it is also ex-
pressed at low level in some types of normal tissues, such as
thymus, spleen, and lymphohemopoetic cells (3–5), WT p53
derived self-MHC–self-peptide complexes may also repre-
sent thymic and/or peripheral tolerogens, thereby prevent-
ing immune responses (6–14). This is particularly true for
class I MHC–peptide complexes expressed by bone mar-
row derived cells in the thymus, as such expression would
cause negative selection of immature thymic T cells with
high avidity for self-MHC–self-peptide complexes (6–11).
In the case of p53, this intrathymic deletion of potentially
self-p53-reactive T cells could result in a peripheral T cell
repertoire purged of CTL precursors with sufficient avidity
to recognize natural WT p53 epitopes presented by class I
MHC molecules on tumor cells. Several studies in mice
and man, however, have provided conflicting results of
whether class I MHC–restricted CTL are functionally tol-
erant of WT p53 (15–22).
We have recently devised an experimental strategy (23)
that exploits species differences between Hu and murine (Mu)
WT p53 protein sequences (24) to circumvent Hu WT
p53-specific T cell tolerance and obtain HLA-restricted CTL
specific for epitopes from Hu p53.
 
 
 
HLA-A2.1
 
2
 
 (A2.1
 
2
 
)
transgenic (Tg) mice (25) were used to generate A2.1-
restricted CTL with high avidity for endogenously pro-
cessed, nonhomologous Hu WT p53 peptides. The Hu
WT p53-specific CTL obtained were able to lyse a broad
variety of p53-overexpressing Hu tumor cells yet did not
recognize nontransformed Hu targets (23). Hu p53 pep-
tides that were homologous to Mu WT p53 sequences did
not induce CTL responses capable of lysing tumor cells, re-
gardless of whether these peptides had high, intermediate,
or low binding affinity to A2.1 (23). Considering that not
all of the nonhomologous Hu WT p53 peptides that bound
 
1
 
Abbreviations used in this paper:
 
 A2.1, HLA-A2.1; Hu, human; Mu, mu-
rine; Tg, transgenic; WT, wild-type.
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A2.1 were capable of inducing a CTL response (23), this
left unresolved the issue of whether self tolerance, or some
other mechanism, was responsible for nonresponsiveness to
homologous p53 peptides.
To explore the possibility that class I MHC–restricted
CTL are tolerant of WT p53, we took advantage of p53
 
2/2
 
mice (26) backcrossed onto HLA-Tg mice expressing a
chimeric class I molecule, A2.1/K
 
b
 
, which contains the 
 
a
 
-1
and 
 
a
 
-2 domains of the HLA-A2.1 molecule, and the 
 
a
 
-3
domain of Mu H-2K
 
b
 
 (23, 25, 27, 28). The expression of
the chimeric A2.1/K
 
b
 
 molecule allows A2.1-restricted Mu
T cells to interact sufficiently with the 
 
a
 
-3 domain of the
transgene product via their Mu CD8 coreceptor during
cognate recognition of A2.1-peptide complexes in thymus
and periphery (25, 27–33). Furthermore, the Ag processing
and presentation machinery in A2.1/K
 
b
 
-Tg mice and Hu
cells are sufficiently similar to present the same CTL epi-
topes (23, 25, 28, 34, 35). Also, the TCR repertoire in man
and A2.1/K
 
b
 
-Tg mice has been demonstrated to be suffi-
ciently diverse to respond to the same A2.1-peptide com-
plexes (23, 36–38). The p53
 
2/2
 
 A2.1/K
 
b
 
 mice do not ex-
press Mu WT p53 protein (26) and therefore would not be
tolerant of self-p53 epitopes presented by A2.1. Although
p53 is required for thymocyte apoptosis induced by ioniz-
ing radiation (26, 39) or adenosine deaminase deficiency
(40), apoptotic cell death of thymocytes and mature T cells
as a result of exposure to compounds that mimic TCR en-
gagement during negative selection has been shown to be
independent of p53 expression (26, 41). Except for a puta-
tive effect due to the lack of expression of self-MHC–p53
peptide complexes, repertoire selection of T cells in p53
 
2/2
 
and p53
 
1/1
 
 A2.1/K
 
b
 
 mice is anticipated to be identical. In
this report, we compared the capability of p53
 
2/2
 
 and
p53
 
1/1
 
 
 
A2.1/K
 
b
 
-Tg mice to mount A2.1-restricted CTL
responses after immunization with A2.1-binding WT p53
peptides that were either homologous or nonhomologous
in sequence between Hu and Mu WT p53.
 
Materials and Methods
 
Mice.
 
The p53
 
2/2
 
 mice (26) were obtained from Tyler Jacks
(Massachusetts Institute of Technology) and mated with line 6
A2.1/K
 
b
 
-Tg (23, 25, 28). Progeny were interbred, and offspring
screened for mice that were p53
 
2/2
 
 and expressed A2.1/K
 
b
 
. Line
22 A2.1-Tg mice were H-2
 
b/b
 
 and heterozygous for the trans-
gene, which contains the 
 
a
 
-1, -2, and -3 domain of A2.1 (23,
25). C57BL/6 mice were purchased from the breeding colony of
The Scripps Research Institute (TSRI). Mice were propagated
and maintained under specific pathogen free conditions in our vi-
varium at TSRI. All experimental procedures were performed
according to the National Institutes of Health Guide for the Care
and Use of Laboratory Animals.
 
Peptides.
 
The selection of synthetic peptides representing se-
quences within the Hu WT p53 protein as well as their binding
affinities for A2.1 have been reported (23). Synthetic WT p53
peptides that were homologous and nonhomologous to Mu WT
p53 sequences and had either high (Hu p53.65-73, 129-137, 187-
195, 264-272, and Mu p53.261-269) or intermediate (Hu p53.149-
157, 187-197, 210-218, 255-264, and 322-330) A2.1-binding af-
 
finity were used in these studies (Table 1) (23). Peptides were
synthesized by the core facility of TSRI using a synthesizer
(model 430A; Applied Biosystems Foster City, CA). Purity was
ascertained by mass spectrometry and reverse-phase HPLC analy-
sis on a Vydac C
 
18
 
 column (Hesperia, CA).
 
Cell Lines.
 
Previously described cell lines and transfectants
used in these studies included T2-A2.1/K
 
b
 
 (T2A2K
 
b
 
), Jurkat-A2.1
(JA2), the H-2
 
b/b
 
 thymoma line EL4, EL4-A2.1/K
 
b
 
 (EA2K
 
b
 
), the
naturally A2.1-expressing, p53-deficient osteosarcoma line Saos-2,
and this same line transfected with a Hu mutant p53 gene, Saos-
2/143 (23, 25, 27, 42, 43). To obtain EA2K
 
b
 
.1p53 transfectants,
EL4 cells were cotransfected with 10 
 
m
 
g of plasmid containing a
genomic clone of A2.1/K
 
b
 
 (27) and 2 
 
m
 
g of pC53-4.2N
 
3
 
 con-
taining a Hu mutant p53 cDNA linked to the neomycin resis-
tance gene (44), as described (27). The corresponding parental and
p53-transfected lines expressed similar levels of A2.1 (Saos-2, Saos-
2/143) or A2.1/K
 
b
 
 (EA2K
 
b
 
, EA2K
 
b
 
.1p53) as detected by flow
cytometry (27). The 10(3) Balb/c fibroblast cell line, which lacks
endogenous Mu p53 and a transfectant of the line that expresses a
Mu p53 gene containing a mutation at residue 215, were kindly
provided by Drs. Dirk Dittmer and Arnold Levine (Princeton
University) (42, 45).
 
Peptide Priming of p53
 
2
 
/
 
2
 
 and p53
 
1
 
/
 
1
 
 A2.1/K
 
b
 
-Tg Mice and
Propagation of CTL.
 
Mice were injected s.c. at the base of the
tail with 100 
 
m
 
g of the indicated WT p53 peptide and 120 
 
m
 
g of
the I-A
 
b
 
-binding synthetic T helper peptide representing residues
128-140 of the hepatitis B virus core protein (36) emulsified in
100 
 
m
 
l of IFA (23). After 10 d, spleen cells of primed mice were
cultured with irradiated A2.1/K
 
b
 
-Tg LPS-activated spleen cell
stimulators that had been pulsed with the priming WT p53 pep-
tide at 5 
 
m
 
g/ml and Hu 
 
b
 
2
 
-microglobulin at 10 
 
m
 
g/ml in complete
RPMI media (RPMI1640 containing 10% vol/vol fetal calf se-
rum, 25 mM Hepes, 2 mM glutamine, 5 
 
3
 
 10
 
2
 
5
 
 M 
 
b
 
-mercapto-
ethenol and 50 
 
m
 
g/ml gentamycin) (23, 25, 28). After 6 d, the re-
sultant effector cells were assayed in a 4-h 
 
51
 
Cr-release assay (27)
at various E/T ratios for lytic activity against T2A2K
 
b
 
 and EL4 tar-
gets that had been pulsed with either the priming WT p53 pep-
tide, an unrelated A2.1-binding peptide, or no peptide. Immuni-
zation of mice with a given peptide as well as the subsequent
effector cell cultures and 
 
51
 
Cr-release assays were performed si-
multaneously for p53
 
2/2
 
 and p53
 
1/1
 
 A2.1/K
 
b
 
-Tg mice. A poly-
clonal, A2.1-restricted CTL line (p53
 
2/2
 
 A2K
 
b
 
 187) derived from
peptide-primed p53
 
2/2
 
 A2.1/K
 
b
 
 mice and specific for Hu WT
p53.187-197 was established by weekly restimulation of effector
CTL with irradiated JA2 cells that had been pulsed with 5 
 
m
 
g of the
indicated p53 peptide, irradiated C57BL/6 spleen filler cells, and 2%
(vol/vol) rat Con A supernatant (23, 27). The polyclonal, A2.1-
restricted CTL line (A2 149) specific for Hu WT p53.149-157
has been established from peptide-primed A2.1-Tg mice as previ-
ously reported (23). CTL clones specific for Hu WT p53.187-197
(p53
 
2/2
 
 A2K
 
b
 
 187 clone 4) and 149-157 (A2 149 clone 5) were de-
rived by limiting dilution (46) of effector cell populations origi-
nally obtained from peptide primed p53
 
2/2
 
 A2.1/K
 
b
 
 and A2.1-
Tg mice, respectively. Stimulators used for CTL cloning were
peptide-pulsed JA2 cells. Lysis of EA2K
 
b
 
 and EA2K
 
b
 
.1p53 as well
as cytokine- and noncytokine-pretreated Saos-2 and Saos-2/143
targets by Hu WT p53-specific CTL lines and clones was deter-
mined in a 5-h 
 
51
 
Cr-release assay (27). Cytokine-pretreated tar-
gets had been exposed for 20 h to both rIFN-
 
g
 
 (R&D Systems,
Minneapolis, MN) at 20 ng/ml and rTNF-
 
a
 
 (R&D Systems) at 3
ng/ml (23). Anti-A2.1 inhibition was performed by exposure of
 
51
 
Cr-labeled target cells to the anti-A2.1 mAb PA2.1 at saturat-
ing, nontoxic concentrations (23, 47). 
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Origin and Use of Vaccinia Recombinants.
 
The vaccinia recom-
binant, vv-A2.1, which expresses the HLA-A2.1 molecule (48)
was kindly provided by Dr. M. Nishimura (Surgery Branch, Na-
tional Cancer Institute). The vPE16 (49) vaccinia recombinant,
which expresses the gp160 of the human immunodeficiency virus
type 1, was kindly provided by Drs. Jack Bennink and Jonathan
Yewdell (National Institute of Allergy and Infectious Diseases).
Target cells were infected as monolayers with 20 PFU per cell for
1 1/2 h in RPMI containing 0.1% BSA. Virus was removed, and
cells incubated 4 h in complete RPMI. Monolayers were dis-
rupted by trypsinization, and cells labeled with 
 
51
 
Cr as previously
described (27).
 
Results
 
Immunogenicity of A2.1-binding WT p53 Peptides in p53
 
2
 
/
 
2
 
and p53
 
1
 
/
 
1
 
 A2.1/K
 
b
 
-Tg Mice. Spleen cells from mice primed
with homologous and nonhomologous A2.1-binding WT
p53 peptides were restimulated with peptide in vitro and
tested for an A2.1-restricted, peptide-specific CTL response.
As reported, p531/1 A2.1/Kb-Tg mice could mount an A2.1-
restricted CTL response specific for several nonhomologous
Hu WT p53 peptides, including 65-73, 149-157, and 264-
272, the latter two of which have been shown to represent
naturally processed CTL epitopes (Table 1) (23). Also as re-
ported, these mice failed to develop A2.1-restricted CTL
specific for the remaining homologous and nonhomologous
Hu WT p53 peptides tested, including 129-137, 187-195,
187-197, 210-218, and 255-264 (23). As anticipated, p532/2
A2.1/Kb mice responded to the same three nonhomologous
Hu p53 peptides recognized by p531/1 A2.1/Kb mice, demon-
strating a comparable level of lytic activity. A lack of A2.1-
restricted CTL responses by p532/2 A2.1/Kb-Tg mice was
also observed with the remaining nonhomologous pep-
tides, as well as with three out of four of the homologous
WT p53 peptides (187-195, 255-264, and 322-330) which
are identical in sequence in Hu and Mu p53 (Table 1). In
contrast, however, a strong A2.1-restricted, peptide-spe-
cific CTL reponse was induced in p532/2 as opposed to
p531/1 A2.1/Kb-Tg mice after priming with the homolo-
gous WT p53.187-197 peptide (Table 1 and Fig. 1 A). Also,
the amount of lysis obtained with responder spleen cells
from p532/2 A2.1/Kb-Tg mice immunized with the Mu
WT p53.261-269 peptide was about twofold higher as
compared with CTL derived from p531/1 A2.1/Kb-Tg
mice (Table 1). Mu WT p53.261-269 is identical with Hu
p53.264-272 at all but one amino acid residue, and has an
equivalent high affinity for A2.1 (23). Significantly, the
concentration of Mu WT p53.261-269 peptide required to
obtain half-maximum lysis of T2A2Kb targets by CTL de-
rived from p532/2 versus p531/1 A2.1/Kb-Tg mice was
z10-fold lower (5.2 3 1028 M versus 4.6 3 1027 M) (Fig.
1 C). This was in contrast to the comparable avidity dem-
onstrated by p531/1 and2/2 A2.1-restricted CTL specific for
the nonhomologous Hu WT p53 epitopes 149-157 and
264-272 (Fig. 1, B and D). As may be anticipated from lack
of tolerance against the Hu WT 264-272 peptide, there is
no cross-reactive recognition of the Mu 261-269 peptide
by the Hu WT 264-272–specific CTL, and vice-versa.
The peptide specificity and the A2.1 restriction of the
CTL reponses shown in Table 1 and Fig. 1 were evidenced
by the failure of these CTL both to lyse T2A2Kb cells
pulsed with unrelated A2.1-binding peptides, and to respond
to A2.1/Kb-negative targets pulsed with the priming pep-
tide (data not shown). It is of interest that A2.1-restricted
CTL derived from p532/2 A2.1/Kb-Tg mice and specific
for the homologous 11-mer peptide p53.187-197 did not
recognize the 9-mer peptide p53.187-195, even though
the 9-mer had an 1.4-fold higher binding affinity for A2.1
(23) (data not shown).
The Homologous WT p53.187-197 Peptide Is Naturally
Processed and Presented by A2.1-expressing Cells from Mice and
Man. A prerequisite for tolerance induction by any self
peptide is its ability to be endogenously processed and
transported into the endoplasmic reticulum for association
with class I MHC molecules (50). To determine whether the
homologous WT p53.187-197 peptide is actually presented
Figure 1. Efficiency of peptide recognition by p53-specific CTL de-
rived from p532/2 (closed circle) and p531/1 (open circle) A2.1/Kb-Tg mice.
Responder spleen cells from peptide-primed p532/2 and p531/1 A2.1/
Kb-Tg mice were restimulated in vitro with the indicated priming pep-
tide. After 6 d, effector CTL were assayed at an E/T ratio of 30:1 for lytic
activity against T2A2Kb targets and the same cells pulsed with (A) Hu
WT p53.187-197, (B) Hu WT p53.149-157, (C) Mu WT p53.261-269,
and (D) Hu WT p53.264-272 at the indicated concentrations.836 Wild-type p53-specific T Cell Tolerance
as naturally processed T cell epitope by A2.1 on the surface
of Mu and Hu cells, both a peptide-specific, polyclonal
CTL line (p532/2 A2Kb 187) and a CTL clone (p532/2
A2Kb 187 clone 4) were established from p532/2 A2.1/Kb-
Tg mice and tested for p53-specific recognition of Mu and
Hu cell lines transfected with Hu p53, EA2Kb.1p53 and
Saos-2/143, respectively (Fig. 2, A and C). As a positive
control for p53-specific, A2.1-restricted lysis, the poly-
clonal CTL line A2 149 and the A2 149 CTL clone 5, both
of which were derived from A2.1-Tg mice and specific for
the natural CTL epitope Hu WT p53.149-157 (23), were
included in these studies (Fig. 2, B and D). Comparison of
the levels of lysis of the p53 transfectants relative to the pa-
rental target lines indicated that both WT p53.187-197 and
149-157 were endogenously processed and presented by
Mu and Hu cells. Recognition was A2.1-restricted, as lysis
was inhibited by an A2.1-specific antibody (data not shown).
To obtain substantial Ag-specific lysis of A2.1-expressing
Saos-2/143 cells by p532/2 A2Kb 187 CTL clone 4 as op-
posed to A2 149 CTL clone 5, targets had to be pretreated
by IFN-g and TNF-a (Fig. 2, C and D), a method that is
known to facilitate TCR-mediated Ag recognition and tar-
get cell lysis by increasing the numbers both of MHC-pep-
tide complexes and of adhesion molecules expressed on the
cell surface (51, 52). The failure of the particular p532/2
A2Kb 187 CTL clone 4 to lyse untreated Saos-2/143 cells
was consistent with the previous finding that CTL from
A2.1/Kb-Tg mice are at a disadvantage in recognition of
cells expressing A2.1 as compared with A2.1/Kb, due to
the inability of Mu CD8 to interact with the Hu a-3 do-
main of the A2.1 molecule (23, 25, 27, 28, 31). However,
due to their in vivo selection and stimulation in the absence
of a sufficient participation by Mu CD8, CTL from A2.1-
Tg mice, such as A2 149 clone 5, express TCRs with un-
usually high affinity for the relevant A2.1-peptide complex
and thus require less peptide Ag for their CD8-indepen-
dent target cell recognition (23, 25, 53). A2 149 CTL clone
5 as opposed to p532/2 A2Kb 187 CTL clone 4 was there-
fore able to lyse untreated Saos-2/143 targets.
The Mu p53.261-269 Self-peptide is Presented by A2.1 on
Murine Cells. Previous studies had demonstrated the Hu
analogue of the Mu p53.261-269 peptide was endoge-
nously processed and presented in association with A2.1
(23). However, as the Mu and Hu peptides differed at one
residue (Table 1) it was possible this difference affected the
presentation of the Mu peptide, resulting in incomplete
tolerance induction. This could explain its recognition in
both p53-deficient and -sufficient animals. To determine if
the Mu WT p53.261-269 peptide was presented by A2.1
Figure 2. Recognition of naturally processed WT p53 epitopes by
A2.1-restricted CTL. The responder CTL line and clone specific for WT
p53.187-197 and derived from p532/2 A2.1/Kb-Tg mice was (A) p532/2
A2Kb 187 and (C) p532/2 A2Kb 187 clone 4, respectively. The responder
CTL line and clone specific for Hu WT p53.149-157 and derived from
(p531/1) A2.1-Tg mice was (B) A2 149 and (D) A2 149 clone 5, respec-
tively. CTL lines and clones were assayed for cytotoxicity against the fol-
lowing targets: EA2Kb (open circles), EA2Kb.1p53 transfectants (closed cir-
cles), untreated p53-deficient Saos-2 (open squares), Saos-2 pretreated with
IFN-g and TNF-a (closed squares), untreated Saos-2/143 p53-transfectants
(open triangle), and Saos-2/143 pretreated with IFN-g and TNF-a (closed
triangles).
Figure 3. The Mu WT p53.261-269 peptide is endogenously pro-
cessed and presented in association with HLA-A2.1 on the surface of vv-
A2.1–infected murine cells. The A2.1 restricted, Mu WT p53.261-269
peptide specific CTL were used as effectors in a 5 h 51Cr-release assay in
which 10(3) tumor cells (A), or 10(3) Mu p53 transfectants (B) were in-
fected with a vaccinia recombinant expressing either the HLA-A2.1 mol-
ecule (closed triangles), or gp 160 (closed circles).837 Theobald et al.
on Mu cells, a transfectant of the mouse 10(3) cell line
which expresses high levels of Mu p53, was infected with a
recombinant strain of vaccinia virus that expresses the A2.1
molecule, vv-A2.1. As a control for the effect of viral in-
fection, cells were infected by a recombinant strain encod-
ing the gp160 of HIV-1 (vPE16). As presented in Fig. 3,
the 10(3) Mu p53 transfectant expressing the A2.1 mole-
cule was specifically lysed by a CTL population specific for
the Mu 261-269 peptide epitope. Neither the p53-defi-
cient parental line, 10(3), nor the 10(3) Mu p53 transfec-
tant infected with vPE16 rather than vv-A2.1 were lysed
by these same effectors. Therefore, the Mu WT p53.261-
269 peptide is presented by cells that express both Mu p53
and A2.1.
Discussion
The combination of p532/2 and p531/1 A2.1/Kb-Tg
mice was used as a model to determine if normal levels of
expression of WT p53 self-peptides presented by A2.1 re-
Table 1. Immunogenicity of A2.1-binding WT p53 Peptides in p532/2A2.1/Kb-Tg and p531/1A2.1/Kb-Tg Mice
E/T
Percent specific lysis
WT p53 peptide p532/2 A2.1/Kb-Tg p531/1 A2.1/Kb-Tg
Position Sequence T2A2Kb T2A2Kb 1 Pe* T2A2Kb T2A2Kb 1 Pe
Hu 65-73 RMPEAAPPV 30 5 44 4 31
10 3 16 2 13
Hu 129-137 ALNKMFCQL 3 0 324 5
3 623 0
Hu 149-157 STPPPGTRV 30 4 57 2 52
31 1 1 1 8
Hu 187-195 GLAPPQHLI 3 0 335 1
3 101 1
Hu 187-197 GLAPPQHLIRV 30 1 84 213
31 3 2 1 0
Hu 210-218 NTFRHSVVV 3 0 444 4
3 021 1
Hu 255-264 ITLEDSSGNL 30 2 210 1
3 002 0
Hu 264-272 LLGRNSFEV 30 3 42 3 57
3 1 10 1 14
Mu 261-269 LLGRDSFEV 30 1 82 1 45
3 1 37 0 16
Hu 322-330 PLDGEYFTL 60 11 12 ND ND
67 1 N D N D
Responder spleen cells from peptide-primed p532/2 and p531/1 A2.1/Kb-Tg mice were restimulated in vitro with the indicated priming peptide.
After 6 d, effector cells were assayed for cytotoxicity against T2A2Kb targets and the same cells pulsed with the priming peptide at 1026 M. Data are
representative for at least two independent experiments for each peptide and a total of at least four mice per strain and peptide. Amino acid residues
that are homologous to the MuWT p53 sequence are in bold type. Nonhomologous residues are underlined.
*Pe, peptide.838 Wild-type p53-specific T Cell Tolerance
sult in functional tolerance. The studies demonstrate that
the A2.1-restricted CTL response to the homologous WT
p53.187-197 self-peptide was eliminated by self tolerance
in p531/1 A2.1/Kb-Tg mice. Also, comparison of the levels
of lysis by effector cells specific for the Mu WT p53.261-
269 self-peptide indicates that CTL with a significantly lower
avidity were recruited in p531/1 relative to the p532/2
strain of A2.1/Kb-Tg mice. These findings are consistent
with a scenario in which functional tolerance of class I
MHC–restricted T cells to WT p53 results in either elimi-
nation of all p53-specific CTL (as with p53.187-197) or
elimination of CTL with high avidity for the relevant class I
MHC–peptide complexes (as with p53.261-269), while
those with low avidity persist. Recent studies demonstrate
that low avidity T cells can escape the negative selection
process and emerge into the periphery (54–57).
However, the data further suggest that gaps in the T cell
repertoire that are independent of p53 expression also oc-
cur, as not all of the homologous and nonhomologous WT
p53 peptides with high or intermediate A2.1-binding affin-
ity were capable of inducing a CTL response in either strain
of Tg mice. Such gaps may reflect lack of expression or
positive selection of TCRs of the relevant specificity, or
deletion attributable to the presence of crossreactive epi-
topes contributed by other proteins (10, 11, 58–60).
It is of interest that the WT p53.187-197 specific CTL
obtained from p532/2 A2.1/Kb mice do not lyse EA2Kb
targets unless they are transfected with p53 and contain
high levels of the protein. Similarly, the EA2Kb targets
were not lysed by the Mu 261-269–specific CTL (data not
shown). As is the case in normal lymphohemopoetic cells,
EL4 cells express only low levels of WT p53 (Hernandez,
J., and L.A. Sherman, unpublished observation). Therefore,
these results support our previous findings that normal lev-
els of expression of p53 are insufficient for recognition by
CTL raised against p53 peptides (23). Nevertheless, these
same low numbers of class I MHC–peptide complexes are
sufficient to achieve tolerance of high avidity CTL, as ob-
served in these studies. Previous reports have demonstrated
that the amount of Ag required for negative selection is less
than that required for recognition by effector T cells (61, 62).
Several Hu WT p53 peptides, such as 149-157, 187-197,
and 264-272, that have been shown in this and a previous
study (23) to be immunogenic in Tg mice and to represent
naturally processed CTL epitopes, have also been demon-
strated to stimulate Hu PBL primarily in vitro and to in-
duce an A2.1-restricted, peptide-specific CTL response
(19–21). Whereas CTL from Tg mice were able to lyse Hu
p53 transfectants and/or Hu tumor cells (23), this has not
been reported for CTL from Hu PBL (19–21), thereby
raising the possibility that the latter represent low avidity
T cells that have survived p53-specific tolerance induction.
This hypothesis is supported by our observation that A2.1-
restricted CTL with apparently higher avidity for the Mu
WT p53.261-269 self-peptide were aborted in p531/1
A2.1/Kb-Tg mice, whereas low avidity CTL could be in-
duced. It should be emphasized that Mu WT p53.261-269
differs by only one conservative amino acid exchange from
the naturally processed Hu WT p53.264-272 T cell epitope
and is bound by A2.1 with an equivalent high affinity (23).
In contrast to our results with Mu WT p53.261-269 and
to studies with Hu PBL (19-21), we could not detect A2.1-
restricted CTL with even low avidity for the WT p53.187-
197 T cell epitope in p531/1 A2.1/Kb-Tg animals. The mo-
lecular and biological reasons for these discrepancies are as
yet unclear. As demonstrated by the data in Figs. 2 and 3,
both peptides are endogenously presented in association with
A2.1 on the surface of Mu cells. However, we cannot ex-
clude the possibility that they are endogenously presented
at different densities. It is possible the Mu WT p53.261-
269 epitope is processed and/or presented less efficiently
than the p53.187-197 epitope. This could result in less effi-
cient tolerance induction, but would not necessarily ex-
plain the difference in responsiveness to p53.187-197 by
mouse and human CTL. Alternatively, the lower A2.1 bind-
ing affinity of p53.187-197 relative to Mu p53.261-269
(23) in conjunction with the low level of expression of the
A2.1/Kb transgene relative to the level of expression of
conventional MHC molecules (28), could be directly or
indirectly involved. For example, the primary in vitro se-
lection of Hu PBL derived, peptide-specific CTL involved
repeated cycles of restimulation with Hu stimulators ex-
pressing high levels of A2.1 and pulsed with high concen-
trations of synthetic peptide in the presence of exogenous
T cell growth promoting cytokines (19–21). Such condi-
tions may promote expansion of low avidity CTL specific
for peptides with intermediate A2.1-binding affinity, such
as p53.187-197 (19–21, 63). However, the in vivo priming
of A2.1/Kb-Tg mice expressing low levels of A2.1/Kb, fol-
lowed by one cycle of in vitro restimulation of responder
spleen cells with peptide-pulsed A2.1/Kb stimulators (in
the absence of exogenous cytokines) may not be sufficient
to induce T cells with low avidity for peptides that repre-
sent intermediate (WT p53.187-197) as opposed to high
(Mu WT p53.261-269) A2.1 binders. It may be anticipated
that low avidity T cells would be the ones most dependent
for their stimulation on large numbers of MHC–peptide
complexes, which in turn, would be fewer for peptides
with lower affinity for A2.1. Future experiments will deter-
mine if altered experimental conditions can lead to induc-
tion of murine CTL specific for p53.187-197. Alterna-
tively, A2.1-positive humans and these A2.1/Kb-Tg mice
that have been demonstrated to be sufficiently similar in se-
lecting A2.1-restricted T cells specific for peptides with
high binding affinity to A2.1 could differ considerably from
each other in their selection of low avidity T cells specific
for self-peptides with intermediate A2.1-binding affinity (38).
In several recent papers, the immune response of BALB/c
mice to a Mu p53 peptide was contrasted with that same
peptide containing a point mutation (Mu p53.234-240 and
236 M to I) (15–17). Although immunization with peptide
in adjuvant resulted in responsiveness only to the mutated
sequence (15, 16), a response to the WT peptide was ob-
tained when these same mice were injected with dendritic
cells pulsed with peptide (17). These results indicated that it
was more difficult to obtain a response to the WT versus839 Theobald et al.
the mutant p53 sequence, consistent with an effect on the
repertoire due to self tolerance. By using p532/2 mice, our
results have directly demonstrated the influence of self tol-
erance on T cell recognition of p53.
In summary, this study shows functional tolerance of
high avidity CTL specific for naturally processed WT p53
peptides presented by A2.1. The data also demonstrate the
flexibility of WT p53-specific tolerance, as the extent by
which low avidity CTL survived the induction of self-tol-
erance varied between the particular class I MHC–p53 pep-
tide combinations. These residual low avidity CTL, how-
ever, could provide an opportunity for immunotherapy of
tumors that express high levels of p53 (17, 18). Given the
variability of the effect observed on the repertoire by self-
tolerance to different peptides, as well as variability of re-
sponsiveness due to different modes of immunization, it is
likely that the success of the immunotherapy directed to-
wards self-proteins will require careful examination of re-
sponses to each MHC-peptide complex. Furthermore, given
the fact that low level expression of p53, such as that ob-
served in normal cells and tumors expressing nonmutant
p53, such as EL4, is insufficient for cell lysis, it is further
likely that the level of presentation of p53 peptides by indi-
vidual tumors will also determine the success of such im-
munotherapy.
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